Jeffrey W. Albers Sells 20,000 Shares of Blueprint Medicines Corp (NASDAQ:BPMC) Stock

Blueprint Medicines Corp (NASDAQ:BPMC) CEO Jeffrey W. Albers sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $81.73, for a total value of $1,634,600.00. Following the transaction, the chief executive officer now directly owns 48,961 shares in the company, valued at approximately $4,001,582.53. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of BPMC traded up $0.92 during trading hours on Wednesday, hitting $79.49. The company had a trading volume of 541,639 shares, compared to its average volume of 462,819. Blueprint Medicines Corp has a 52-week low of $44.58 and a 52-week high of $102.98. The firm has a market cap of $4.13 billion, a P/E ratio of -14.75 and a beta of 1.55. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 0.16. The stock’s 50 day moving average price is $93.69 and its 200 day moving average price is $84.43.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Thursday, August 1st. The biotechnology company reported ($2.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.92) by ($0.12). Blueprint Medicines had a negative return on equity of 73.73% and a negative net margin of 4,268.74%. The firm had revenue of $5.11 million for the quarter, compared to analysts’ expectations of $1.39 million. During the same quarter last year, the company posted ($0.62) EPS. The firm’s revenue was down 87.7% on a year-over-year basis. On average, research analysts expect that Blueprint Medicines Corp will post -8.45 EPS for the current fiscal year.

BPMC has been the topic of several recent analyst reports. Raymond James reaffirmed a “market perform” rating on shares of Blueprint Medicines in a research report on Wednesday, August 14th. BidaskClub lowered Blueprint Medicines from a “buy” rating to a “hold” rating in a research report on Wednesday, August 14th. Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a research report on Monday, June 17th. Robert W. Baird initiated coverage on Blueprint Medicines in a report on Thursday, July 18th. They set an “outperform” rating and a $120.00 target price on the stock. Finally, Canaccord Genuity boosted their price target on Blueprint Medicines from $105.00 to $120.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Blueprint Medicines presently has an average rating of “Buy” and an average price target of $110.11.

A number of institutional investors and hedge funds have recently made changes to their positions in BPMC. Rockefeller Capital Management L.P. raised its stake in Blueprint Medicines by 4,594.1% during the 2nd quarter. Rockefeller Capital Management L.P. now owns 798 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 781 shares during the last quarter. Whittier Trust Co. purchased a new stake in Blueprint Medicines during the 2nd quarter valued at $97,000. Ladenburg Thalmann Financial Services Inc. raised its stake in Blueprint Medicines by 62.8% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,097 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 423 shares during the last quarter. Trexquant Investment LP purchased a new stake in Blueprint Medicines during the 2nd quarter valued at $203,000. Finally, Flinton Capital Management LLC purchased a new stake in Blueprint Medicines during the 2nd quarter valued at $211,000. Institutional investors and hedge funds own 97.45% of the company’s stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Recommended Story: What is an Initial Public Offering (IPO)?

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.